Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600062's Earnings Yield (Joel Greenblatt) % is ranked better than 84.95% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 2.995
vs SHSE:600062: 11.48
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. China Resources Double-Crane Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 17.78%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
SHSE:600062 vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
China Resources Double-Crane Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
China Resources Double-Crane Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,836 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 11.49% mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Earnings Yield (Joel Greenblatt) % of 11.49% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 12% above median its historical median of 10.24. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % has ranged from 3.67 to 14.78. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #152 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is China Resources Double-Crane Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % too high?
China Resources Double-Crane Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 11.49% is 12% above median its 10-year median of 10.24. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 14.78. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.00. China Resources Double-Crane Pharmaceutical Co's value of 11.49% is 283.6% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #152 out of 1010 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #152 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places China Resources Double-Crane Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.00. China Resources Double-Crane Pharmaceutical Co's value of 11.49% is 283.6% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Earnings Yield (Joel Greenblatt) % has ranged from 3.67 to 14.78 over the past decade. While the company's 10-year median is 10.24 vs. the industry median of 3.00, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.00, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 11.49% is 283.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % is 11.49%, which is 12% above median its own 10-year median of 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.85, compared to a current price of ¥16.05 — trading 14.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 11.49%, which is 12% above median its 10-year median of 10.24 and 283.6% above the Drug Manufacturers industry median of 3.00. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Earnings Yield (Joel Greenblatt) % is 11.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.05 is trading 14.9% below its estimated GF Value™ of ¥18.85.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Earnings Yield (Joel Greenblatt) %: 11.49% (12% above median its 10-year median of 10.24)
GF Value™: ¥18.85 vs. price of ¥16.05 (14.9% below fair value)
Industry Position: 283.6% above the Drug Manufacturers median (#152 of 1010)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
